AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR)

Profile: AVANIR Pharmaceuticals, Inc. focuses on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States and Canada. Its lead product candidate includes Zenviatm, which has completed three Phase III clinical trials for the treatment of pseudobulbar affect; and a Phase III trial for the treatment of patients with diabetic peripheral neuropathic pain. The company also offers Abreva, an over-the-counter product for the treatment of cold sores. AVANIR Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California.

LTN’s Options Trading Filter saw unusual Call buying volume on Thursday in AVANIR Pharmaceuticals, Inc.
There were 18,523 Call contracts traded.

On the Put side: Just 123 Put contracts changed hands.

Today’s traded Put/Call ratio is 0.01, meaning that there less than 1 Call bought for each Put.
The Unusual Trading Action Alerts

1. Unusual Call Volume

2. Low Put/Call Ratio

Note: This P-C ratio imbalance implies that players are hedging their positions in anticipation of a stock move. Today’s unusual volume activity confirms that players are re-balancing their portfolios.
Shares of closed at 4.23 + 0.36- (9,30%) Thursday

The stock closed Wednesday at 3.87, and opened Thursday at 3.88.

The price was between 3.81, and on the day 4.25.

Volume of 16,877,650/shrs is 400 + % more than the 90 day average volume of 3,994,410/shrs .
AVNR is trading above its 50 and 200 Day Moving Averages.

The stock’s 52 week low is 1.31, and 52 week high is 5.80, it has a P/E ratio of N/A , EPS -0.36 , RSI is 66.68, and Div and Yield of N/A (N/A%).